Key result
Amlodipine is an effective and safe first-line antihypertensive agent with strong evidence for cardiovascular event reduction.
Why the study?
Does amlodipine improve blood pressure and patient outcomes in patients with hypertension?
Does amlodipine improve blood pressure and patient outcomes in patients with hypertension?
Amlodipine is an effective and safe first-line antihypertensive agent with proven cardiovascular event reduction benefits.
Answers are grounded in this paper and cite their sources.
Supports first-line amlodipine in hypertension; leaves open need for updated head-to-head trials.
OBJECTIVES: Hypertension is well established as a major risk factor for cardiovascular disease. Although there is undeniable evidence to support the beneficial effects of antihypertensive therapy on morbidity and mortality, adequate blood pressure management still remains suboptimal. Research into the treatment of hypertension has produced a multitude of drug classes with different efficacy profiles. These agents include β-blockers, diuretics, ACE inhibitors, angiotensin receptor blockers and calcium channel blockers. One of the oldest groups of antihypertensives, the calcium channel blockers are a heterogeneous group of medications. METHODS: This review paper will focus on amlodipine, a dihydropyridine calcium channel blockers, which has been widely used for 2 decades. RESULTS: Amlodipine has good efficacy and safety, in addition to strong evidence from large randomised controlled trials for cardiovascular event reduction. CONCLUSIONS: Amlodipine should be considered a first-line antihypertensive agent.
No takes yet. Share an insight, caveat, or question.
Fares et al. (2016) conducted a review in Hypertension. Amlodipine was evaluated. Amlodipine is an effective and safe first-line antihypertensive agent with strong evidence for cardiovascular event reduction.
Synapse has enriched 10 related papers. Consider them for comparative context: